European Commission okays state aid for pharma companies
This article was originally published in Scrip
Executive Summary
In good news for pharmaceutical companies hit by government austerity measures, the European Commission has okayed a German scheme that exempts struggling companies from the mandatory rebates and price freezes intended to cut costs. Firms should welcome the decision because it means EU countries can use state aid to balance controlling public spending with helping pharma companies survive in difficult conditions, says Johan Ysewyn, a partner at the law firm Covington & Burling.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.